Findings from a post-hoc analysis of the C017 open-label extension (OLE) study demonstrated sustained long-term reduction in seizure frequency with cenobamate, approved as adjunctive treatment in patients with focal onset seizures, after five years across eight different etiology categories
Angelini Pharma and SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and oncology, today announced that more than 100,000 patients1 have been treated globally with cenobamate, an innovative anti-seizure medication (ASM) developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science.
- Key findings of the report highlight the ongoing toll that multiple parallel crises have on mental health in Europe, emphasizing the urgent need for individuals, communities, societies, and policymakers to improve mental well-being across the continent and foster a healthier and more resilient society for current and future generations
- Eco-anxiety, a pre-traumatic stress disorder where men
Findings from a post-hoc analysis of the C017 open-label extension study demonstrated 23.6% of patients receiving adjuvant treatment with Cenobamate achieved sustained seizure freedom for at least one year.
Angelini Pharma and The European House – Ambrosetti, an Italian Think Tank, today announced the publication of the second edition of the “Headway – A new roadmap in Brain Health: Focus Epilepsy” report as part of an ongoing partnership aimed at sharing knowledge, raising awareness and promoting better health for people living with epilepsy in Europe.
Agreement gives Angelini Pharma the option to an exclusive license to develop and commercialize highly innovative brain-penetrant biologic therapeutics in epilepsy.
Angelini Pharma i Norden har en helhetssyn på vårdsektorn och menar att det inte bara är läkemedelsbehandling som gör skillnad – flera andra faktorer spelar också in. Läs hela artikeln om vad företaget gör inom hjärnhälsa!
Birger Jarlsgatan 6D
114 34 Stockholm
Sweden
